On the stock market since 2025, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
An investor who bought at the very peak is down 76% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It pays out $17.29 per share each year — regular cash for whoever holds the stock.
A loss of $103.7M against $0 in annual sales.
This stock swings about 2.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, IMRA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: IMRA is a high-risk stock — not yet profitable, and its future rides on its product catching on.